SATB2 and renal cell carcinoma: The results suggest that targeting SATB2 and associated SWI/SNF complexes may represent a promising therapeutic strategy for the treatment of RCC with high YAP levels, although the study was conducted only in cell models and thus should be further validated in in vivo settings [120].